Lupin to present Phase 1 Data on STING agonist at the ESMO Congress 2025
The presentation will provide qualitative insights into its safety, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity in patients with solid tumors
The presentation will provide qualitative insights into its safety, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity in patients with solid tumors
AstraZeneca to invest $50bn in manufacturing and R&D to support domestic sourcing
Merck will showcase results in innovative solutions in HIV treatment and prevention
UZEDY (risperidone) extended-release injectable suspension for subcutaneous use is indicated for use every one or two months for the treatment of schizophrenia in adults
The company will present new data from across over 20 cancer types and multiple treatment settings at European Society for Medical Oncology Congress 2025
Facility marks cornerstone of $50 billion investment in medicines R&D and manufacturing in America
The company plans to use the funds raised from the net proceeds to repay or prepay certain loans
Lupin's partnership program is designed to foster collaborations with companies looking to extend their product lifecycles
New study presents a human-relevant stress model for assessing potential therapeutics
This collaboration aims to combine Molcure’s cutting-edge AI technology with Boehringer Ingelheim’s extensive expertise in drug discovery
Subscribe To Our Newsletter & Stay Updated